Two‐year abrocitinib in atopic dermatitis: Are we reaching the new targets?

Nevertheless, the study represents a valuable benchmark for long-term JAK1 inhibition in AD.In conclusion, this study confirms that sustained, multidomain control of moderate-to-severe AD is achievable with abrocitinib in many patients.Its broader significance lies in showing that the new language of AD management is no longer purely theoretical.The next challenge will be to move beyond static response thresholds towards longitudinal disease activity, fluctuation control, biomarker-defined remission and, ultimately, disease modification.